Umbilical cord-derived mesenchymal stem cells inhibit growth and promote apoptosis of HepG2 cells.

Hepatocellular carcinoma is the fifth most common type of cancer worldwide and remains difficult to treat. The aim of this study was to investigate the effects of mesenchymal stem cells (MSCs) derived from the umbilical cord (UC‑MSCs) on HepG2 hepatocellular carcinoma cells. UC‑MSCs were co‑cultured with HepG2 cells and biomarkers of UC‑MSCs were analyzed by flow cytometry. mRNA and protein expression of genes were determined by reverse transcription‑polymerase chain reaction and flow cytometry, respectively. Passage three and seven UC‑MSCs expressed CD29, CD44, CD90 and CD105, whereas CD34 and CD45 were absent on these cells. Co‑culture with UC‑MSCs inhibited proliferation and promoted apoptosis of HepG2 cells in a time‑dependent manner. The initial seeding density of UC‑MSCs also influenced the proliferation and apoptosis of HepG2 cells, with an increased number of UC‑MSCs causing enhanced proliferation inhibition and cell apoptosis. Co‑culture with UC‑MSCs downregulated mRNA and protein expression of α‑fetoprotein (AFP), Bcl‑2 and Survivin in HepG2 cells. Thus, UC‑MSCs may inhibit growth and promote apoptosis of HepG2 cells through downregulation of AFP, Bcl‑2 and Survivin. US-MSCs may be used as a novel therapy for treating hepatocellular carcinoma in the future.

[1]  M. Dong,et al.  CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF. , 2013, Oncology reports.

[2]  M. Stojkovic,et al.  Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice , 2013, Scientific Reports.

[3]  O. Lee,et al.  In Vivo Fluorescence Imaging Reveals the Promotion of Mammary Tumorigenesis by Mesenchymal Stromal Cells , 2013, PloS one.

[4]  A. Cleton-Jansen,et al.  Mesenchymal stem cell transformation and sarcoma genesis , 2013, Clinical Sarcoma Research.

[5]  S. Zhang,et al.  The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells , 2012, Breast Cancer Research and Treatment.

[6]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[7]  M. Parola,et al.  Stem and progenitor cells in liver regeneration and repair. , 2011, Cytotherapy.

[8]  Q. Ye,et al.  Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97‐H cell line , 2010, Cancer science.

[9]  F. Marini,et al.  Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. , 2010, Lung cancer.

[10]  Min Zhang,et al.  Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions , 2010, Journal of Translational Medicine.

[11]  Y. Xia,et al.  Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice , 2010, Oncogene.

[12]  Han Liu,et al.  Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. , 2009, Cancer letters.

[13]  D. Troyer,et al.  Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. , 2009, Cancer letters.

[14]  Han Liu,et al.  Alpha fetoprotein is a novel protein‐binding partner for caspase‐3 and blocks the apoptotic signaling pathway in human hepatoma cells , 2009, International journal of cancer.

[15]  I. Weinstein,et al.  HINT1 inhibits β‐catenin/TCF4, USF2 and NFκB activity in human hepatoma cells , 2009, International journal of cancer.

[16]  Ralph Weissleder,et al.  Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy , 2009, Proceedings of the National Academy of Sciences.

[17]  M. Weiss,et al.  Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. , 2009, Cancer research.

[18]  C. Shao,et al.  Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1 , 2009, Leukemia.

[19]  W. Lau,et al.  Hepatocellular carcinoma: current management and recent advances. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.

[20]  S. Karahuseyinoglu,et al.  Functional Structure of Adipocytes Differentiated from Human Umbilical Cord Stroma‐Derived Stem Cells , 2008, Stem cells.

[21]  M. Najimi,et al.  Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. , 2008, Gastroenterology.

[22]  M. Weiss,et al.  Concise Review: Wharton's Jelly‐Derived Cells Are a Primitive Stromal Cell Population , 2008, Stem cells.

[23]  M. Weiss,et al.  Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors , 2007, Cancer Gene Therapy.

[24]  R. Tuan,et al.  Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow , 2007, Stem cells.

[25]  Z. Trajanoski,et al.  Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation , 2007, BMC Genomics.

[26]  M. Raffeld,et al.  Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma , 2006, The Journal of experimental medicine.

[27]  Franca Fagioli,et al.  Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow , 2006, Journal of cellular biochemistry.

[28]  M. Weiss,et al.  Human Umbilical Cord Matrix Stem Cells: Preliminary Characterization and Effect of Transplantation in a Rodent Model of Parkinson's Disease , 2006, Stem cells.

[29]  Shiaw-Min Hwang,et al.  Cytokine interactions in mesenchymal stem cells from cord blood. , 2005, Cytokine.

[30]  Q. Xie,et al.  Human umbilical cord Wharton's Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. , 2005, Chinese medical journal.

[31]  W. Lau,et al.  The continuing challenge of hepatic cancer in Asia. , 2005, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[32]  V. Mazzaferro,et al.  Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.

[33]  S. Hwang,et al.  Differential Gene Expression Profiling of Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells by DNA Microarray , 2005, Stem cells.

[34]  M. Andreeff,et al.  Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.

[35]  M. Min,et al.  Transformation of Human Umbilical Mesenchymal Cells into Neurons in vitro , 2004, Journal of Biomedical Science.

[36]  M. Lindvall,et al.  Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. , 2003, Experimental and molecular pathology.

[37]  Lau Wy.  Management of hepatocellular carcinoma. , 2002, Journal of the Royal College of Surgeons of Edinburgh.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  W. Lau.  Primary liver tumors. , 2000, Seminars in surgical oncology.

[40]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[41]  Catherine M. Verfaillie,et al.  Pluripotency of mesenchymal stem cells derived from adult marrow , 2007, Nature.

[42]  Mohamed A. Ali,et al.  The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma. , 2004, The Egyptian journal of immunology.

[43]  F. Tomaselli,et al.  DNA Microarray , 2002 .

[44]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.